Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab
BackgroundTo demonstrate the rare ocular side effects in a patient receiving pembrolizumab and nivolumab for metastatic ovarian cancer.Case presentationA 37-year-old woman with recurrent metastatic ovarian cancer presented with blurred vision and photophobia after receiving pembrolizumab. Ocular fin...
Main Authors: | Wan-Hua Cho, Wei-Yu Chiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Ophthalmology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2022.1021574/full |
Similar Items
-
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01) -
Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
by: Johann Stuby, et al.
Published: (2020-11-01) -
Immune checkpoint inhibitors in pediatric hematologic malignancies
by: I. V. Gribkova
Published: (2023-05-01) -
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
by: Amanda F. Cashen
Published: (2024-10-01) -
Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
by: Fabrice Yves Ndjana Lessomo, et al.
Published: (2023-03-01)